BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $58.22 -0.5%
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q3 EPS of $0.04, $0.14 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $113.4 million versus the consensus estimate of $113.2 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marriott (MAR) Tops Q3 EPS by 19c; Guides EPS Higher
- Seaport Therapeutics, Inc. (SPTX) Misses Q3 EPS by 49c
- Lumentum Holdings (LITE) Tops Q1 EPS by 36c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
